Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Treating Prediabetes in the First Trimester

9 de octubre de 2018 actualizado por: Hilary Roeder, MD, University of California, San Diego

Treating Prediabetes in the First Trimester: A Randomized Controlled Trial

The investigators plan to study a sample of women with prediabetes (diagnosed by Hemoglobin A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL) in the first trimester of pregnancy, and patients will be randomized to first trimester or third trimester treatment; the first trimester group will receive intervention immediately upon diagnosis of prediabetes whereas the third trimester group will receive only routine prenatal care until 28 weeks at which time they will receive intervention.

Intervention is defined as:

  • diabetes education
  • blood glucose monitoring
  • medications as needed
  • growth ultrasounds
  • antenatal testing

The primary outcome is umbilical cord C-Peptide >90th percentile. Secondary outcomes include neonatal fat mass at delivery, infant weight-for-length at 12 months of age, maternal gestational weight gain, and biomarkers (chemicals) measured in the placenta and the baby's umbilical cord blood.

The investigators hypothesize that women who undergo the above intervention in the first trimester will deliver significantly fewer neonates with umbilical cord C-Peptide >90th percentile, and that the neonates will have lower fat mass, and weight-for-length at 12 months. The investigators further hypothesize that a greater proportion of patients undergoing first trimester intervention will have appropriate maternal gestational weight gain as defined by the Institute of Medicine, and a greater proportion will return to prepregnancy weight within 12 months.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

The primary aim of the proposed research is to demonstrate that promoting a normoglycemic intrauterine milieu in women with prediabetes diagnosed in the first trimester of pregnancy with a Hemoglobin A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL will decrease the accumulation of fetal white adipose tissue and development of infant/child obesity during the first year of life. This project is built upon the hypothesis that pregnant subjects with prediabetes randomized in the first trimester of pregnancy to strict glycemic control and pharmacotherapy as needed will have less fetal adiposity and adverse neonatal outcomes than those who receive the diagnosis of prediabetes but do not initiate care until the third trimester.

In the proposed study, 240 women meeting the above criteria for prediabetes at ≤ 15w0d gestation will be randomized to either first trimester or third trimester treatment. Each group will have diabetes education, initiate blood glucose monitoring, begin pharmacotherapy as needed (per established protocol), undergo growth ultrasounds, and antenatal testing. The first trimester arm will receive the above interventions immediately upon diagnosis of prediabetes whereas the third trimester arm will receive only routine prenatal care until 28 weeks at which time they will begin education and treatment. Both groups will be treated identically from 28 weeks until delivery.

In the 2013 the National Institutes of Health (NIH) Gestational Diabetes (GDM) Consensus Conference, the panel was concerned about adopting criteria that would increase prevalence of GDM (i.e. first trimester treatment) without first demonstrating improved outcomes. The results of this proposed trial, will allow us to fill key research gaps; this is the first prospective trial to evaluate the International Associations of Diabetes in Pregnancy Study Groups (IADPSG) recommendations for screening and diagnosing prediabetes in the first trimester.

Findings from this research will quantify the maternal and neonatal benefits and harms of treating women with prediabetes from early pregnancy. Additionally, the cohort of neonates that will result from this study can be followed into childhood to evaluate whether first trimester treatment has benefits beyond those anticipated at birth and may decrease the long-term incidence of obesity and diabetes.

Tipo de estudio

Intervencionista

Inscripción (Actual)

202

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • San Diego, California, Estados Unidos, 92103
        • UC San Diego Health System

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Pregnant women age 18 and above
  • Any ethnic background
  • English- or Spanish-speaking
  • Planned prenatal care/delivery at The University of California, San Diego's Hillcrest Hospital
  • Singleton pregnancy
  • Prediabetes diagnosed prior to 15w0d with HbA1c 5.7-6.4% or FPG 92-125 mg/dL

Exclusion Criteria:

  • Known Type 2 Diabetes (T2DM)
  • T2DM diagnosed with first trimester screening
  • Patients with known maternal/fetal indications for delivery <36w0d
  • Patients presenting for care after 15w0d

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: First Trimester Treatment of Prediabetes

Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

Standardized treatment of prediabetes per California Diabetes and Pregnancy Program "Sweet Success"

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing
Comparador activo: Third Trimester Treatment of Prediabetes

Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

Standardized treatment of prediabetes per California Diabetes and Pregnancy Program "Sweet Success"

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Umbilical Cord C-Peptide >90th percentile
Periodo de tiempo: 1 day (Collected at the time of delivery)
1 day (Collected at the time of delivery)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Neonatal fat mass
Periodo de tiempo: Within 48 hours of delivery
Neonatal fat mass will be measured using an anthropometric model using weight, length, and flank skinfold thickness.
Within 48 hours of delivery
Adherence to the Institute of Medicine (IOM) guidelines for gestational weight gain
Periodo de tiempo: Weight gain will be measured from immediately preconception until delivery
The IOM recommends that underweight women (BMI<18.5kg/m2) gain 28-40lbs, normal women (BMI 18.5-24.9 kg/m2) gain 25-35lbs, overweight women (BMI 25.0-29.9 kg/m2) gain 15-25lbs and obese women (BMI≥30 kg/m2) gain 11-20 lbs.
Weight gain will be measured from immediately preconception until delivery
Return to prepregnancy weight
Periodo de tiempo: After 1 year post delivery
After 1 year post delivery

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
birthweight
Periodo de tiempo: At delivery
At delivery
birthweight percentile
Periodo de tiempo: At delivery
At delivery
Infant gender
Periodo de tiempo: At delivery
At delivery
Ponderal index
Periodo de tiempo: At delivery
Weight/length^3
At delivery
Neonatal Intensive Care Unit (NICU) Admission
Periodo de tiempo: Within 10 days after birth
Within 10 days after birth
Infant weight-for-length
Periodo de tiempo: 6 months and 12 months after delivery
6 months and 12 months after delivery
Need for pharmacotherapy to control hyperglycemia
Periodo de tiempo: From 5 weeks gestation until time of delivery
From 5 weeks gestation until time of delivery
Birth trauma
Periodo de tiempo: At delivery
Shoulder dystocia, brachial plexus injury
At delivery
Mode of delivery
Periodo de tiempo: At delivery
Spontaneous delivery, operative vaginal delivery, cesarean delivery
At delivery
Indication for delivery
Periodo de tiempo: At delivery
At delivery
Total gestational weight gain
Periodo de tiempo: From immediately preconception until delivery
From immediately preconception until delivery
Postpartum weight retention
Periodo de tiempo: Within 1 year of delivery
Within 1 year of delivery
Diagnosis of Preeclampsia
Periodo de tiempo: From 20 weeks gestation until 6 weeks postpartum
From 20 weeks gestation until 6 weeks postpartum

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Hilary A Roeder, MD, UC San Diego Health System
  • Investigador principal: Gladys A Ramos, MD, UC San Diego Health System
  • Investigador principal: Thomas R Moore, MD, UC San Diego Health System

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de julio de 2013

Finalización primaria (Actual)

1 de junio de 2016

Finalización del estudio (Actual)

15 de junio de 2017

Fechas de registro del estudio

Enviado por primera vez

15 de agosto de 2013

Primero enviado que cumplió con los criterios de control de calidad

20 de agosto de 2013

Publicado por primera vez (Estimar)

21 de agosto de 2013

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de octubre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

9 de octubre de 2018

Última verificación

1 de octubre de 2018

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir